10 serious COVID patients given Israeli drug, leave hospital in one day
The data showed a 40% decrease in lung inflammation from treatment – from 55% to 15%, as seen in chest X-rays * Rambam Health Care Campus doctor: ‘Results extremely impressive’
A laboratory image shows a healthy lung, a sick lung and lung treated with MesenCure.
(photo credit: Courtesy)
An Israeli biotechnology company has claimed a 100% success rate in the first 10 patients treated with its drug as part of an early-stage clinical trial at Rambam Health Care Campus in Haifa.
The company, Bonus BioGroup, presented the preliminary findings of its Phase I/II trial to peers at the International Society for Cell & Gene Therapy conference in New Orleans last week and shared the results in a statement released to the Tel Aviv Stock Exchange.
No comments:
Post a Comment